Microalbuminuria prevalence study in hypertensive patients with type 2 diabetes mellitus in Singapore

Singapore Medical Journal

Volumn 47, Issue 4, 2006, Pages 315-320

  Wu, Akira Y T ^a   Tan, C B ^b   Eng, P H K ^c   Tan, K T ^a   Lim, S C ^d   Tan, E K ^a  

^a MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^b SINGHEALTH POLYCLINICS   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d ALEXANDRA HOSPITAL   (Singapore)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Hypertension; Macroalbuminuria; Microalbuminuria

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; SINGAPORE;

ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; SINGAPORE;

EID: 33645741144     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403-18.
2. Stamler J. Vaccaro O, Neaton JD. Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-44.
3. Wild S, Roglic G. Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53.
4. Epidemiology and disease control department, Ministry of Health, Singapore National Health Survey 1998, Singapore.
5. Lee G. End-stage renal disease in the Asian-Pacific region. Semin Nephrol 2003; 23:107-14.
6. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-8.
7. Miettinen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27:2039.
8. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 1996; 19:305-12.
9. American Diabetes Association. Diabetic Nephropathy. Position Statement. Diabetes Care 2002;25 (Suppl 1):85S-9S.
10. Spooren PF, Lekkerkerker JF, Vermes I. Micral-Test: a qualitative dipstick test for micro-albuminuria. Diabetes Res Clin Pract 1992; 18:83-7.
11. Mather HM, Chaturvedi N, Kehely AM. Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus. Diabet Med 1998; 15:672-7.
12. Varghese A. Deepa R, Rema M, Mohan V. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J 2001: 77:399-402.
13. Tomura S, Kawada K, Saito K, et al. Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Am J Nephrol 1999; 19:13-20.
14. Lee WR, Lim HS, Thai AC, et al. A window on the current status of diabetes mellitus in Singapore - the Diabcare-Singapore 1998 study. Singapore Med J 2001; 42:501-7.
15. Wu A, Kong NCT. de Leon F, et al. A prospective evaluation of microalbuminuria in hypertensive type 2 diabetics in Asia: the MAPS (MicroAlbuminuria Prevalence) study. Diabetologia 2004; 48:17-26.
16. Haneda M, Kikkawa R, Togawa M, et al. High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1992; 6:181-5.
17. Mogensen CE. Microalbuminuria predicts clinical proleinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-60.
18. John L, Rao PS, Kanagasabapathy AS. Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care 1994; 17:888-90.
19. Cooper ME, Frauman A, O'Brien RC, et al. Progression of proteinuria in type 1 and type 2 diabetes. Diabet Med 1988; 5:361-8.
20. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001; 60:2041-55.
21. Ritz E, Tarng DC. Renal disease in type 2 diabetes. Nephrol Dial Transplant 2001; 16 Suppl 5:11-8.
22. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17:1247-51.
23. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289:2560-72.
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 38). BMJ 1998; 317:703-13.
25. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-62.
26. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 Suppl 2:14S-21S.
27. Ma S, Cutter J, Tan CE, Chew SK, Tai ES. Associations of diabetes mellitus and ethnicity with mortality in a multiethnic Asian population: data from the 1992 Singapore National Health Survey. Am J Epidemiol 2003; 158:543-52.
28. Cutter J, Tan BY, Chew SK. Levels of cardiovascular disease risk factors in Singapore following a national intervention programme. Bull World Health Organ 2001; 79:908-15.
29. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-8.
30. Brenner BM. Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
32. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-61.